Vktx nasdaq.

SAN DIEGO, Sept. 11, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...

Vktx nasdaq. Things To Know About Vktx nasdaq.

VKTX-3.57%. MDGL -0.85%. SPX-0.20% ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...Viking Therapeutics, Inc. (VKTX) has been on a downward spiral lately with significant selling pressure. After declining 24.8% over the past four weeks, the stock looks well positioned for a trend ...Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Earnings Call Transcript (Insider Monkey) Feb-08-23 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (PR Newswire) Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the …Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...

Mar 29, 2023 · Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ... Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent …5 Best Weight Loss Stocks To Invest In Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2023 Earnings Call Transcript 10 Stocks Wall Street Analysts and Billionaires Are Crazy About 15 Best-Performing ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Earnings Call Transcript (Insider Monkey) Feb-08-23 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (PR Newswire) Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the …

Viking Therapeutics Inc share price live 10.090, this page displays NASDAQ VKTX stock exchange data. View the VKTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Viking Therapeutics Inc real time stock price chart below. You can find more details by visiting …Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, California, is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and ...Dec 4, 2023 · Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ... Standing squarely in the bull camp, BTIG analyst Justin Zelin rates VKTX a Buy along with a $20 price target. This target puts the upside potential at a whopping 221%. This target puts the upside ...

Dec 1, 2023 · According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00.

Viking Therapeutics Inc stock price live 13.010, this page displays NASDAQ VKTX stock exchange data. View the VKTX premarket stock price ahead of the market session or assess the after hours quote.

Viking Therapeutics (NASDAQ:VKTX) shares gained over 5% in extended trading on Monday after the drugmaker reported positive findings from an ongoing study of its lead drug candidate, VK2809.VK2809 ...Viking Therapeutics, Inc ( NASDAQ: VKTX ), a clinical-stage biopharmaceutical firm developing treatments for metabolic and endocrine disorders, plans to raise $55.0 million in its upcoming IPO ...Viking Therapeutics (NASDAQ:VKTX) shares gained over 5% in extended trading on Monday after the drugmaker reported positive findings from an ongoing study of its lead drug candidate, VK2809.VK2809 ...SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Viking Therapeutics, Inc. Common Stock (VKTX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading ...Jun 11, 2021 · Viking Therapeutics Inc (Symbol: VKTX) saw options trading volume of 5,067 contracts, representing approximately 506,700 underlying shares or approximately 53.5% of VKTX's average daily trading ... Wirestock/iStock via Getty Images. Introduction. Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biotech firm working on treatments for metabolic and endocrine issues.Their main drug, VK2809 ...Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...Dec 1, 2023 · View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Fintel reports that on August 8, 2023, Stifel reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 142.45% Upside. As of August 2 ...Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare disease programs include novel selective thyroid... VKTX : 12.28 (+6.23%) Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire - Thu Sep 7, 3:05PM CDT.

Apr 10, 2023 · Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of $3.50. If an investor was to purchase shares of VKTX stock at the current price ... The latest price target for . Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023.The analyst firm set a price target for 32.00 expecting VKTX to rise ...

Viking Therapeutics, Inc. Common Stock (VKTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. May 18, 2023 · NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (-2.28%) -$0.28. ... (VKTX-2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's ... Fintel reports that on May 16, 2023, Oppenheimer maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Outperform recommendation.. Analyst Price Forecast Suggests 35.91% Upside. As of ...Dec 6, 2021 · Viking Therapeutics, Inc. (VKTX) has been on a downward spiral lately with significant selling pressure. After declining 24.8% over the past four weeks, the stock looks well positioned for a trend ... Viking Therapeutics, Inc. (NASDAQ:VKTX) is a San Diego, California-based biotech company developing therapeutics for patients that are suffering from endocrine and metabolic disorders.SAN DIEGO, Feb. 8, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its ...Feb 9, 2023 · Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany ParticipantsStephanie Diaz - Investor... Viking Therapeutics (NASDAQ: VKTX) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its Phase 1 study of ...

Viking Therapeutics, Inc. (VKTX) has been on a downward spiral lately with significant selling pressure. After declining 24.8% over the past four weeks, the stock looks well positioned for a trend ...

Viking Therapeutics Inc (NASDAQ:VKTX) $11.83 0.11[0.94%] Last update: 4:20PM (Delayed 15-Minutes) Get Real Time Here $11.83 0[0.00%] After-Hours News …

Feb 9, 2023 · Average portfolio weight of all funds dedicated to VKTX is 0.02%, a decrease of 20.95%. Total shares owned by institutions decreased in the last three months by 1.25% to 27,896K shares. Viking Therapeutics Inc stock price (VKTX) NASDAQ: VKTX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Viking Therapeutics Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock.That's the story for Viking Therapeutics ' ( VKTX 6.46%) share price so far this year. The stock jumped nearly 26% year to date by early March. It subsequently gave up all of those gains and then ...Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,829 shares of the biotechnology company’s stock, valued at approximately $2,072,000. Rhumbline …Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the …Viking Therapeutics, Inc ( NASDAQ: VKTX ), a clinical-stage biopharmaceutical firm developing treatments for metabolic and endocrine disorders, plans to raise $55.0 million in its upcoming IPO ...That number of contracts represents approximately 709,400 underlying shares, working out to a sizeable 51.3% of VKTX's average daily trading volume over the past month, of 1.4 million shares.Dec 6, 2021 · Viking Therapeutics, Inc. (VKTX) has been on a downward spiral lately with significant selling pressure. After declining 24.8% over the past four weeks, the stock looks well positioned for a trend ... May 18, 2023 · NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (-2.28%) -$0.28. ... (VKTX-2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's ... Here's why they chose Bluebird Bio (NASDAQ: BLUE), Travere Therapeutics (NASDAQ: TVTX), and Viking Therapeutics (NASDAQ: VKTX). The upside is huge, but beware of the risks .

Principal Financial Group Inc. bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to the company in its most recent Form 13F filing ...Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, a dual agonist of GLP-1 and ...Feb 9, 2023 · Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany ParticipantsStephanie Diaz - Investor... Instagram:https://instagram. doximity incaa4dividen yielddog training business insurance VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ... stock portfolio toolhow much is a 1943 steel penny worth today VKTX soared on obesity data, while Incyte INCY suffered a setback for ruxolitinib extended-release ... The Nasdaq Biotechnology Index has gained 0.68% in the past five trading sessions. Among the ... what is the best online banking app NASDAQ: Viking Therapeutics Inc (VKTX) = 11.83 USD. Provided by Alpha Vantage. Viking Therapeutics Inc stock (VKTX) in USD. 1 VKTX = 11.83 USD. 1 month. 6 months. 1 year. 5 years. Hold over 40 currencies to convert and send money at any time. Open an account.Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX 7.03%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are ...